Please assess the completion status of the following clinical trial:

Trial Title: RHA Redensity - Perioral Rhytids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Outpatient, male or female of any race, 22 years of age or older~* Moderate to severe perioral rhytids of grade 2 or 3 on the four-point PR-SRS (ranging from 0-3)~* Willing to abstain from facial aesthetic procedures/therapies that could interfere with study evaluations~* Able to follow study instructions and complete all required visits.~* Sign the IRB-approved ICF, Photographic Release Form and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study- related procedures being performed.~Exclusion Criteria :~* Female subjects that are pregnant, breast-feeding or of childbearing potential and not practicing reliable birth control~* Known hypersensitivity/allergy to any component of the study devices~* Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders~* Clinically significant active skin disease within 6 months~* History of connective tissue disease

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TEOSYAL RHA Redensity (Type: EXPERIMENTAL): Injection of TEOSYAL RHA Redensity into the perioral lines (n=150). Up to 6.0 mL (max 3 mL for upper and max 3 mL for lower) injected into the dermis, including the superficial dermis. Touch-up treatment provided at 2 weeks.
- No Treatment (Type: NO_INTERVENTION): No treatment control group (n=52).

Based on this trial design, predict the completion outcome and termination type (if applicable).